Recent Updates
Recently added Catalysts
EW Positive Sentiment

Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features

Monday, November 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Edwards Lifesciences announced that the PROGRESS Trial results show transcatheter aortic valve replacement (TAVR) is superior to clinical surveillance for moderate aortic stenosis patients with at-risk features. The trial's primary endpoint, which included death or heart failure events at two years, was significantly improved with TAVR. These findings could influence future management strategies for this patient group.

Market Sentiment Analysis

POSITIVE FACTORS

  • TAVR shows superiority over clinical surveillance.
  • Results indicate improved outcomes for moderate AS patients.
  • Trial results may change treatment protocols.

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced results from the PROGRESS Trial, marking a turning point in the management of moderate aortic stenosis (AS). The trial demonstrated that transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance in the primary composite endpoint of death or heart failure events at two years in moderate AS patients with at-risk features. The late-breaking results were presented at Transcatheter Cardiovascular Th

Frequently Asked Questions

What did the PROGRESS Trial demonstrate?

The trial showed TAVR is superior to clinical surveillance for moderate AS.

What was the primary endpoint of the trial?

The primary endpoint was death or heart failure events at two years.

Who presented the trial results?

The results were presented at the Transcatheter Cardiovascular Therapeutics meeting.

What condition does TAVR target?

TAVR targets moderate aortic stenosis patients with at-risk features.

ShareAdd on Google
Tags: EW Edwards Lifesciences TAVR aortic stenosis PROGRESS Trial clinical surveillance
Last updated: Nov 2, 2026

Biotech snapshot

Cash runway
$4253M liquidity · $0M/mo burn
Low dilution risk